Panarum
Panarum Corporation is developing its Proteoral® technology for the delivery of therapeutic polypeptides, which works by innocuously opening intercellular junctions of the intestinal epithelium. The company is privately owned. It was founded in 2017 with investments from angel investors.
Panarum Corporation is developing its Proteoral® technology for the delivery of therapeutic polypeptides, which works by innocuously opening intercellular junctions of the intestinal epithelium.
The company is privately owned. It was founded in 2017 with investments from angel investors. In 2020 it secured its first international venture capital investment.
Authors and Contacts
Article
